Posted by Michael Wonder on 29 Aug 2017
Health Canada approves Tresiba, a new basal insulin for type 1 and 2 diabetes
28 August 2017 - The new once-daily, ultra-long-acting insulin provides a glucose-lowering effect beyond 42 hours.
Novo Nordisk today announced that Health Canada has approved Tresiba (insulin degludec injection), a new basal insulin for the once-daily treatment of adults with diabetes mellitus to improve glycemic control.
Tresiba is the first insulin to be added to Canada's national register of innovative drugs by Health Canada since the register was established in 2006.
